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Abstract
Introduction Paclitaxel is used widely in the treatment of breast
cancer. Not all tumors respond to this drug, however, and the
characteristics that distinguish resistant tumors from sensitive
tumors are not well defined. Activation of the spindle assembly
checkpoint is required for paclitaxel-induced cell death. We
hypothesized that cyclin-dependent kinase (CDK) 1 activity and
CDK2 activity in cancer cells, which reflect the activation state
of the spindle assembly checkpoint and the growth state,
respectively, predict sensitivity to paclitaxel.
Methods Cell viability assays and DNA and chromatin
morphology analyses were performed in human breast cancer
cell lines to evaluate sensitivity to paclitaxel and the cell cycle
response to paclitaxel. We then examined the specific activities
of CDK1 and CDK2 in these cell lines and in xenograft models
of human breast cancer before and after paclitaxel treatment.
Protein expression and kinase activity of CDKs and cyclins were
analyzed using a newly developed assay system.
Results In the cell lines, biological response to paclitaxel in vitro
did not accurately predict sensitivity to paclitaxel in vivo. Among
the breast cancer xenograft tumors, however, tumors with
significantly increased CDK1 specific activity after paclitaxel
treatment were sensitive to paclitaxel in vivo, whereas tumors
without such an increase were resistant to paclitaxel in vivo.
Baseline CDK2 specific activity was higher in tumors that were
sensitive to paclitaxel than in tumors that were resistant to
paclitaxel.
Conclusions The change in CDK1 specific activity of xenograft
tumors after paclitaxel treatment and the CDK2 specific activity
before paclitaxel treatment are both associated with the drug
sensitivity in vivo. Analysis of cyclin-dependent kinase activity in
the clinical setting could be a powerful approach for predicting
paclitaxel sensitivity.
Introduction
Paclitaxel is used widely in the treatment of breast cancer and
several other solid tumors [1-6]. Paclitaxel is not effective in all
tumors, however, and the characteristics that distinguish
resistant tumors from sensitive tumors are not well defined.
Identifying the tumor molecular characteristics associated with
resistance to or sensitivity to paclitaxel would help determine
which patients are most likely to benefit from paclitaxel
therapy.
Paclitaxel resistance has been attributed to a variety of mech-
anisms, including upregulation of antiapoptotic Bcl-2 familyPage 1 of 10
(page number not for citation purposes)
CDK: cyclin-dependent kinase; DMEM: Dulbecco's modified Eagle's medium; FBS: fetal bovine serum; IC50: 50% inhibitory concentration; PBS: 
phosphate-buffered saline.
Breast Cancer Research    Vol 11 No 1    Nakayama et al.members such as Bcl-2 and Bcl-XL [7,8]; upregulation of
membrane transporters such as mdr1, which increases drug
efflux [9]; point mutations in β-tubulin residues or altered
expression of tubulin isotypes, which impair drug–tubulin bind-
ing [10,11]; upregulation of ErbB2 (HER-2) by inhibition of
cyclin-dependent kinase (CDK) 1, which causes delayed mito-
sis [12]; and high expression of microtubule-associated pro-
tein tau mRNA, which decreases paclitaxel binding to
microtubules and microtubule polymerization [13].
We recently reported that activation of the spindle assembly
checkpoint is required for paclitaxel-induced cell death and
that inactivation of this checkpoint was correlated with sup-
pression of CDK1 activity [14]. CDK1, in combination with
other mitotic cyclins, is a universal master kinase and is
required for the regulation of mitosis [15]. Previous studies
that used CDK inhibitors or dominant-negative CDK1 con-
structs showed that CDK1 plays a critical role in paclitaxel-
induced cell death [16-18]. CDK1 activity may therefore be a
predictor of paclitaxel sensitivity.
Several studies reported that rapidly proliferating tumors have
a higher response rate to chemotherapy [19,20]. Expression
levels of cyclin A and cyclin E are suggested to correlate with
the proliferation state of cancer cells [21,22]. These molecules
are considered to drive the cell cycle by activating CDK2 [23].
Moreover, a correlation between the effectiveness of paclitaxel
and the tumor growth rate has previously been reported [24].
We therefore speculated that high CDK2 activity is required
for increased paclitaxel sensitivity.
In the present study we measured both the kinase activity and
expression level of CDK1 and CDK2 before and after paclit-
axel treatment in human breast cancer cell lines and in
xenograft models of human breast cancer. We defined the
specific activity of CDK as a kinase activity (unit) of its protein
expression (1 μg). We found that changes in CDK1 specific
activity after paclitaxel treatment predicted the paclitaxel sen-
sitivity of breast cancer cells and xenograft tumors. Baseline
CDK2 specific activity was higher in tumors that were sensi-
tive to paclitaxel than in tumors that were resistant to paclitaxel.
Materials and methods
Cell cultures
MDA-MB-231 and MDA-MB-468 human breast cancer cells
were cultured in DMEM–Ham's F12. T47D and MCF-7 human
breast cancer ells were cultured in RPMI 1640 medium. Both
media were purchased from Sigma (St Louis, MO, USA) and
were supplemented with 10% heat-inactivated FBS (Hyclone
Laboratories, Logan, UT, USA) and 1% antibiotic–antimycotic
solution (Gibco Invitrogen, Carlsbad, CA, USA). All cell lines
were maintained at 37°C in a humidified incubator in a 5% car-
bon dioxide atmosphere.
Preparation of cell lysates
Cultured cells were treated with 100 nM paclitaxel (Calbio-
chem, Darmstadt, Germany) for 24, 48, or 72 hours, and then
these cells were frozen immediately at -80°C. At the time of
CDK analysis, the frozen cells were thawed, treated with lysis
buffer (0.1% NP-40, 50 mM Tris–Cl (pH 7.4), 50 mM NaF, 5
mM ethylenediamine tetraacetic acid, 1 mM NaVO3, and 0.2%
proteinase inhibitor cocktail; Sigma), and centrifuged at
10,000 × g for 5 minutes at 4°C. The obtained lysates were
assayed for CDK activity and expression as described below.
Cell viability assay
For cell viability assays, cells were seeded at a concentration
of 5 × 103 cells/well in 100 μl culture medium into 96-well cul-
ture plates and were incubated for 24 hours. Cells were
washed, and fresh culture medium containing various concen-
trations of paclitaxel (0.1 pM to 100 μM) was added. After 72
hours of treatment, 10 μl WST-1/ECS solution (Chemicon
International, Inc., Temecula, CA, USA) was added to each
well, and the plates were incubated at 37°C for 4 hours.
Absorbance was measured at 440 nm on a microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
DNA analysis
For DNA analysis, cells were treated with 100 nM paclitaxel for
24, 48, or 72 hours, after which nonadherent cells were col-
lected from the flask and then the adherent cells removed by
trypsinization. The cells were stained with 50 μg/ml propidium
iodide in PBS-glucose containing ribonuclease A (2 kU/ml;
Sigma) for 1 hour. The DNA content of the cells was measured
using a FACSCalibur flow cytometry system and was analyzed
with ModFit software (BD Biosciences, San Jose, CA, USA).
The DNA content was analyzed at the time corresponding to
the doubling time of each cell line (that is, 24 hours after treat-
ment for the MDA-MB-468 and MDA-MB-231 cells, and 48
hours after treatment for the T47D and MCF-7 cells).
Chromatin morphology analysis
For chromatin morphology analysis, cells were treated with
100 nM paclitaxel for 24, 48, or 72 hours, after which nonad-
herent cells were collected from the flask and then the adher-
ent cells removed by trypsinization. Both cell fractions were
mixed, washed with PBS, smeared onto glass slides by cyt-
ospin centrifugation at 1,000 × g for 5 minutes, and then
stained with aceto-orcein solution (Muto Pure Chemicals Ltd,
Tokyo, Japan) to visualize the chromatin. The morphology was
analyzed under a light microscope at 20× magnification. The
DNA and chromatin morphology was analyzed at the time cor-
responding to the doubling time of each cell line after paclit-
axel treatment (that is, 24 hours after treatment for MDA-MB-
468 and MDA-MB-231 cells, and 48 hours after treatment for
T47D and MCF-7 cells). The MDA-MB-468 and MDA-MB-
231 cells could not be analyzed 48 hours after treatment
because of low viability (<10%) at that time.Page 2 of 10
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For analysis of CDK and cyclin protein expression, the crude
cell lysates containing 2.5 μg total protein were added to the
wells of a newly developed dot-blot device (Sysmex Co.,
Kobe, Japan). The analysis procedure in detail was described
in our previous report [25].
Analysis of cyclin-dependent kinase activity
CDK molecules were selectively precipitated from 50 μg total
protein with 2 μg corresponding anti-CDK1 or anti-CDK2 anti-
body and 20 μl protein A sepharose beads (Amersham Phar-
macia, Uppsala, Sweden) for 1 hour at 4°C. Fifty microliters of
the substrate mixture (containing 10 μg protein substrate (his-
tone H1; Upstate Biotechnology, Lake Placid, NY, USA), 5
mM adenosine 5'-O-(3-thiotriphosphate; Sigma), 20 mM Tris–
Cl (pH 7.4), and 0.1% Triton X-100) was added, and the
beads were incubated under continuous shaking at 37°C for
30 minutes. The substrate mixture was then collected, and the
monothiophosphates introduced as the substrate were
labeled further by incubation with 10 mM iodoacetyl biotin
(Pierce, Rockford, IL, USA) in coupling buffer (100 mM Tris–
Cl (pH 8.5) and 1 mM ethylenediamine tetraacetic acid) for 90
minutes in the dark at room temperature. The reaction was
quenched with β-mercaptoethanol, and 0.4 μg thiophosphor-
ylated substrate was applied to the wells of the Sysmex dot-
blot device. The wells were blocked with 1% bovine serum
albumin for 30 minutes at room temperature, incubated with
fluorescein-labeled streptavidin (Vector Laboratories, Burlin-
game, CA, USA) for 1 hour at 37°C, and washed with Tris-
buffered saline. After that, fluorescent images of the dot-blot
device membrane were evaluated with a Molecular Imager FX
image analyzer (Bio-Rad, Hercules, CA, USA), and the fluores-
cence intensity of the dots was quantified with the Quantity
One program (Bio-Rad).
Cyclin-dependent kinase specific activity
We defined a unit as equivalent to the kinase activity of 1 μg
total protein from CDK1 or CDK2.
Xenograft models of breast cancer
MDA-MB-231 and MDA-MB-468 cells were suspended in
PBS, and T47D and MCF-7 cells were suspended in a solu-
tion of Matrigel (BD, Franklin Lakes, NJ, USA) 50% v/v in PBS.
The suspended cells (5 × 106 cells/mouse) were inoculated
subcutaneously into the mammary fat pads of 6-week-old
female BALB/c nu/nu mice (CLEA Japan Inc., Tokyo, Japan).
Because T47D and MCF-7 cells require estrogen for growth,
17β-estradiol pellets (0.72 mg, 60-day release; Innovative
Research of America, Sarasota, FL, USA) were implanted sub-
cutaneously in the shoulder region of each mouse before inoc-
ulation with the cells. When the tumor masses reached 50 to
80 mm3 (about 10 days after the inoculation), the mice were
given daily intraperitoneal injections of paclitaxel (20 mg/kg
per day, or one-half of the 50% of lethal dose 40 mg/kg, n =
7) or 15% ethanol solution containing 0.9% NaCl as a vehicle
control (n = 8) for 5 days. Two-dimensional tumor measure-
ments were made daily until 12 days after the first dose. The
tumor volume was calculated according to the formula: volume
= π (short diameter2) × (long diameter)/6.
Unpaired two-sample t tests were used to test differences in
tumor size between the control group and the drug-treated
groups. This was approved by the animal ethic committee.
The in vivo CDK specific activity was measured in the tumor
tissues resected from the mice as follows. Tumor-bearing mice
were given a single 20-mg/kg dose of paclitaxel, and 24 hours
later they were killed by cervical dislocation. Tumor tissues
were resected and lysed in lysis buffer with a homogenizer
(HM-100; Sysmex Co.). Welch's t test was used for
comparison.
Results
Sensitivity of breast cancer cell lines to paclitaxel
First, we examined the sensitivity of four human breast cancer
cell lines to paclitaxel in vitro. The 50% inhibitory concentra-
tion (IC50) values determined by cell viability assay were as fol-
lows: MDA-MB-468, 1.8 nM; MDA-MB-231, 2.4 nM; T47D,
4.4 nM; and MCF-7 cells, 7.2 nM.
Results of DNA and chromatin analysis of breast cancer 
cells after paclitaxel treatment in vitro
We next examined the cell cycle response to paclitaxel using
DNA analysis and morphologic analyses of chromatin in each
of the four breast cancer cell lines.
DNA analysis revealed that the G2/M (4N) fraction increased
after paclitaxel treatment by a factor of 1.6 in MDA-MB-468
cells, a factor of 3.9 in MDA-MB-231 cells, a factor of 5.0 in
T47D cells, and a factor of 3.9 in MCF-7 cells (Figure 1a). This
result indicates that paclitaxel interfered with mitosis through
spindle stabilization in each of the four cell lines. In contrast,
the sub-G1 (apoptotic) fraction increased in three cell lines –
by a factor of 4.5 in MDA-MB-468 cells, a factor of 1.8 in
MDA-MB-231 cells, and a factor of 1.6 in T47D cells – but did
not increase in MCF-7 cells.
In the morphologic analysis of chromatin after paclitaxel treat-
ment, MDA-MB-468, MDA-MB-231, and MCF-7 cells showed
ring-like staining (Figure 1b, arrows), indicating that paclitaxel
induced perinuclear microtubule bundles [26]. T47D cells, in
contrast, did not show bundles but did show chromatin con-
densation, which is indicative of cells arrested in mitosis (Fig-
ure 1b, arrowheads).
These results indicated that paclitaxel sensitivity in vitro and
the cell biological response were not correlated in the four cell
lines.Page 3 of 10
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Cell cycle and morphological changes in response to paclitaxel treatment in breast cancer cell linesi l  i  r  t  aclitaxel treat ent in breast cancer cell lines. Cells were treated with 100 nM paclitaxel for 0, 
24, 48, or 72 hours and then stained with (a) propidium iodide or (b) aceto-orcein staining solution. Propidium iodide-stained cells were subjected 
to DNA analysis by flow cytometry. Morphology of orcein-stained chromatin was assessed by light microscopy. Arrowheads indicate typical chroma-
tin condensation staining, and arrows indicate ring-like staining of mitotic cells. The flow cytometry data were analyzed at the time corresponding to 
the doubling time of each cell line (that is, after 24 hours of treatment for the MDA-MB-468 and MDA-MB-231 cells, and after 48 hours for the T47D 
and MCF-7 cells). The MDA-MB-468 and MDA-MB-231 cells could not be analyzed at 48 hours after treatment because of extremely low viability 
(<10%) at that time.Page 4 of 10
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We measured the specific activities of CDK1 and CDK2 in the
four breast cancer cell lines after treatment with 100 nM pacl-
itaxel. This concentration was chosen to ensure that cells were
exposed to levels two log units higher than the IC50 but within
the physiologically tolerable range.
CDK1 specific activity was increased after paclitaxel treatment
in MDA-MB-468, MDA-MB-231, and T47D cells, but not in
MCF-7 cells (Figure 2a, left). The increment of CDK1 specific
activity after the treatment was 6.4 times in MDA-MB-468, 8.5
times in MDA-MB-231, 4.5 times in T47D and 1.7 times in
MCF-7, respectively. In contrast, CDK1 specific activity was
not related to cyclin B expression after paclitaxel treatment in
any of the four cell lines (Figure 2a,b). The magnitude of the
increases in CDK1 specific activity after paclitaxel treatment
correlated strongly with the IC50 values of paclitaxel in the
tested cell lines (R2 = 0.86; data not shown). These results
indicated that the change in CDK1 specific activity after pacl-
itaxel treatment reflected the sensitivity of cells to paclitaxel in
vitro.
Similarly, CDK2 specific activity was increased after paclitaxel
treatment in MDA-MB-468 and T47D cells (Figure 2a, right).
The increment of CDK2 specific activity after the treatment
was 2.1 times in MDA-MB-468 cells and 2.9 times in T47D
cells, respectively. The magnitude of the increases in CDK2
specific activity after paclitaxel treatment, however, did not
correlate significantly with the IC50 values of paclitaxel in the
tested cell lines (R2 = 0.004; data not shown). Cyclin E expres-
sion was not related to CDK2 specific activity after paclitaxel
treatment in any of the four cell lines (Figure 2a,c).
Sensitivity of tumor xenografts to paclitaxel
We established breast cancer xenograft models by implanting
each of the four breast cancer cell lines in nude mice, and then
treated the mice with paclitaxel. Five daily doses of paclitaxel
reduced the mean volume of the MDA-MB-468 and MDA-MB-
231 tumors (Figure 3a,b) but did not affect the volume of the
T47D and MCF-7 tumors (Figure 3c,d). These results indi-
cated that, in this model, MDA-MB-468 cells and MDA-MB-
231 cells were sensitive to paclitaxel and T47D cells and
MCF-7 cells were resistant to paclitaxel in vivo.
Specific activities of CDK1 and CDK2 in breast cancer 
xenografts after paclitaxel treatment in vivo
We next measured the specific activities of CDK1 and CDK2
in breast tumors resected from mice 24 hours after a single
dose of paclitaxel. CDK1 specific activity was significantly
increased after paclitaxel treatment in the MDA-MB-468 and
MDA-MB-231 tumors (Figure 4a). The mean value of CDK1
specific activity before and after the treatment was 0.036 and
0.21 units/ng in MDA-MB-468 cells, and was 0.011 and 0.35
units/ng in MDA-MB-231 cells, respectively (P < 0.01 for
each), both of which were found to be sensitive to paclitaxel in
vivo (Figure 3a,b); these cell lines also had the lowest IC50 val-
ues of paclitaxel among the four cell lines. CDK1 specific activ-
ity was not increased after paclitaxel treatment in the T47D
and MCF-7 tumors (Figure 4a). The mean value of CDK1 spe-
cific activity before and after the treatment is 0.022 and 0.038
units/ng in T47D cells, and is 0.011 and 0.015 units/ng in
MCF-7 cells, respectively, which were not sensitive to paclit-
axel in vivo (Figure 3c,d).
CDK2 specific activity was increased after paclitaxel treatment
only in the MDA-MB-468 tumors (Figure 4b), even though
CDK2 specific activity in vitro was increased after paclitaxel
treatment in both MDA-MB-468 and T47D cells (Figure 2a,
right). Interestingly, the baseline (before paclitaxel treatment)
CDK2 activity was significantly higher in the MDA-MB-468
and MDA-MB-231 tumors than in the T47D and MCF-7
tumors (Figure 4b). The mean value of CDK2 specific activity
before the treatment is 20.3 units/ng in MDA-MB-468 cells,
11.2 units/ng in MDA-MB-231 cells, 2.7 in T47D cells, and
6.5 units/ng in MCF-7 cells, respectively (P < 0.01 for each).
Discussion
We found that an increase in CDK1 specific activity after pacl-
itaxel treatment correlates with sensitivity of the xenografts to
paclitaxel, and a lack of change in CDK1 specific activity cor-
relates with a lack of sensitivity of the xenografts to paclitaxel.
These findings indicate that analysis of CDK1 activity could be
a powerful approach for predicting paclitaxel sensitivity. In our
in vivo experiment, the highest CDK1 specific activity value
observed after paclitaxel treatment in xenografts of the paclit-
axel-resistant T47D and MCF-7 cells was 0.15 units/ng. If this
value was used as the cutoff value to distinguish between
paclitaxel-sensitive and paclitaxel-resistant xenografts, the
CDK1 specific activity would have a positive predictive value
of 100% for the determination of paclitaxel sensitivity in our
studies. Several reports have shown that conventional in vitro
drug sensitivity tests such as the histoculture drug response
assay are about 80% accurate in predicting sensitivity
[27,28]; however, this assay is time consuming and tedious. In
addition, we observed that the variation in IC50 values for pacl-
itaxel determined by cell viability assay between the four cell
lines was less than one order of magnitude (from 1.8 nM to 7.2
nM), which suggests that the conventional assay is difficult to
apply in clinical practice. The results of our current study sug-
gest that our newly developed system for measuring CDK
activity in vivo would allow more accurate prediction of paclit-
axel sensitivity than the conventional assay.
We reported recently that activation of the spindle assembly
checkpoint is required for paclitaxel-induced cell death [14].
Assessing the function of the checkpoint in human cancer by
analyzing mutation of genes or protein expression, however,
would be impractical. Actually, the sensitivity of paclitaxel in
vitro was not consistent with the cell biological response inPage 5 of 10
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with paclitaxel were induced to M-phase arrest and showed
ring-like staining, which was followed by apoptosis, suggest-
ing that both cell lines possessed functional spindle assembly
checkpoints. In contrast, MCF-7 cells did not show any
increase in the sub-G1 fraction after paclitaxel treatment
although they showed ring-like staining and increased in the
G2/M fraction, indicating that the spindle assembly checkpoint
– and consequent induction of apoptosis – was impaired. This
response may be related to the known defect in MCF-7 cells
in caspase 3 [29], which is necessary for paclitaxel-induced
apoptosis [30]. This finding demonstrates that M-phase arrest
in response to paclitaxel treatment does not always reflect the
induction of apoptosis. In the case of T47D cells, in which no
typical ring-like staining was observed, we suspect that there
were point mutations in β-tubulins – including important resi-
dues for drug–tubulin binding or altered expression of tubulin
isotypes. The induction of apoptosis in T47D cells upon treat-
ment with higher concentrations of paclitaxel than the IC50 val-
ues may therefore depend on other checkpoints instead of, or
in addition to, the spindle assembly checkpoint.
Notably, in the absence of paclitaxel treatment, the paclitaxel-
sensitive MDA-MB-468 and MDA-MB-231 xenograft tumors
showed much more rapid growth than the resistant T47D and
MCF-7 tumors (Figure 3). Several studies reported recently
that rapid proliferating tumors have a higher response rate to
chemotherapy [19,20]. Actually, we found that the rapidly
Figure 2
Cyclin-dependent kinase expression and specific activity levels and cyclin expression in breast cancer cell lines. Cells were treated with 100 nM 
paclitaxel for 0, 24, 48, or 72 hours, after which they were harvested, lysed, and assayed. (a) Cyclin-dependent kinase (CDK) 1 (left) and CDK2 
(right) specific activity. (b) Cyclin B expression. (c) Cyclin E expression. U, units.Page 6 of 10
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/11/1/R12growing tumors showed significantly higher CDK2 specific
activity without paclitaxel treatment than did the slowly grow-
ing tumors (Figure 4b). Moreover, a correlation between the
effectiveness of paclitaxel and the tumor growth rate has pre-
viously been reported [24]. CDK2 specific activity in breast
tumors would therefore be another indicator of paclitaxel
sensitivity.
Consequently, accurate prediction could be expected from
the combination assay of CDK1 and CDK2 activities. A clinical
study is needed to validate our concept of predicting sensitiv-
ity to paclitaxel by analyzing the CDK activity in tumor tissues
from patients.
Figure 3
Changes in volume of human breast cancer xenograft tumors in mice after paclitaxel administration. Cells were inoculated subcutaneously into the 
mammary fat pads of female nude mice, and 10 days later paclitaxel (circles) or vehicle (squares) was administered daily by intraperitoneal injection 
for 5 days (arrows). (a) MDA-MB-468 cells. (b) MDA-MB-231 cells. (c) T47D cells. (d) MCF-7 cells. Tumor dimension was measured daily for 12 
days after the first dose. Each point represents the mean (bar, standard deviation) of seven independent measurements of tumor size. Percentage of 
relative tumor growth calculated as the mean tumor volume on each day divided by the mean volume at the time of the first paclitaxel or vehicle 
administration.Page 7 of 10
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Cyclin-dependent kinase specific activity in breast cancer xenograft tissues. Previously untreated tumor-bearing mice were given a single 20-mg/kg 
dose of paclitaxel. Tumor tissues were resected 24 hours later, lysed, immunoprecipitated with (a) anti-cyclin-dependent kinase (CDK) 1 antibody or 
(b) anti-CDK2 antibody, and assayed for kinase activity. Histone H1 was used as the substrate. U, units.Page 8 of 10
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Conclusions
The increase in CDK1 specific activity after paclitaxel treat-
ment indicates that a tumor is sensitive to paclitaxel, and a lack
of change in CDK1 indicates that a tumor is resistant to pacl-
itaxel. The level of CDK2 specific activity before paclitaxel
treatment was shown to correlate with paclitaxel sensitivity in
vivo. Consequently, accurate prediction of paclitaxel sensitivity
could be realized by a combination assay of CDK1 and CDK2
activities. Validation of our concept with a clinical sample will
be needed in future studies.
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